Ascendis Pharma's TransCon PTH Shows Sustained Kidney Function Gains in Trials Lasting Up to 5 Years

• Ascendis Pharma announced pooled trial results showing sustained kidney function improvements with TransCon PTH in adults with hypoparathyroidism treated for up to five years.
• Results from Phase 2 PaTH Forward and Phase 3 PaTHway were presented at Kidney Week 2026.
• The post-hoc analysis covered 139 treated patients, showing early kidney function gains maintained through trial completion.
• Most patients became independent of conventional therapy, with improvements in blood and urinary calcium levels.
• TransCon PTH was generally well tolerated, with no new safety signals; most treatment-emergent adverse events were mild to moderate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260800OMX_____CNEWS_EN_GNW9852765_en) on October 26, 2026, and is solely responsible for the information contained therein.